Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ND-003 in Advanced Solid Tumors
NCT06169579Phase 1Enrolling by invitation
- Sponsor
- Shenzhen NewDEL Biotech Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Jun 2028
- Modality
- Antibody Fragments, Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ND-003 in solid tumor, sponsored by Shenzhen NewDEL Biotech Co., Ltd. Started Feb 2024; status: enrolling by invitation.
02
Drugs
ND-003
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06169579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169579.